A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. | J Infect Dis;206(12): 1844-51, 2012 Dec 15. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection.

Moss, Ronald B; Hansen, Carrie; Sanders, Rebecca L; Hawley, Stephen; Li, Tiejun; Steigbigel, Roy T.

Affiliation

Moss RB; NexBio Inc, San Diego California 92121, USA. rmoss@nexbio.com

J Infect Dis ; 206(12): 1844-51, 2012 Dec 15.

Article in En | MEDLINE | ID: mdl-23045618

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Recombinant Fusion Proteins / Influenza, Human Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Infect Dis Year: 2012 Document type: Article Affiliation country:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Recombinant Fusion Proteins / Influenza, Human Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Infect Dis Year: 2012 Document type: Article Affiliation country: